1. Scrip

ZAI Builds On Sanofi Ties For Lung Cancer Candidate

 
• By Ying Huang

China’s ZAI Lab has in-licensed its third preclinical drug candidate from Sanofi, a novel multi-kinase inhibitor aimed at a non-small cell lung cancer target and other oncology indications. The new agreement indicates ZAI’s R&D strategy of bringing in novel early stage assets with large unmet needs in China and globally.

SHANGHAI - ZAI Lab Ltd., a Shanghai-based biotech start-up company, has entered into a global licensing agreement with Sanofi for a novel multi-kinase inhibitor targeting non-small cell lung cancer (NSCLC), which adds a third preclinical drug candidate to its pipeline from the French firm for treating respiratory system diseases.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia